When one size does not fit all: aid and health system strengthening for Small Island Developing States.

Health System strengthening is high on the agenda of the global health community. We review some of the specific challenges faced by Small Island Developing States in the development of their health systems. We propose a list of action points for aid actors willing to adapt their health programs and interventions.

Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.

OBJECTIVES: Vaccination has been effective in ameliorating the impact of COVID-19. Here, we report vaccine effectiveness (VE) of the nationally available COVID-19 vaccines in Mexico. METHODS: Retrospective analysis of a COVID-19 surveillance system to assess the VE of the BNT162b2, messenger RNA (mRNA)-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1, and CoronaVac vaccines against SARS-CoV-2 infection, COVID-19 hospitalization, and death in Mexico. The VE was estimated using time-varying Cox proportional hazard models in vaccinated and unvaccinated adults, adjusted for age, sex, and comorbidities. VE was also estimated for adults with diabetes, aged ≥60 years, and comparing the predominance of SARS-CoV-2 variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated and 4,792,338 unvaccinated adults between December 24, 2020 and September 27, 2021. The VE against SARS-CoV-2 infection was the highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95% confidence interval [CI] 90.3-92.4) and Ad26.COV2.S (82.2%, 95% CI 81.4-82.9); for COVID-19 hospitalization, BNT162b2 (84.3%, 95% CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95% CI 79.5-83.1), and for mortality, BNT162b2 (89.8%, 95% CI 89.2-90.2) and mRNA-12732 (93.5%, 95% CI 86.0-97.0). The VE decreased for all vaccines in adults aged ≥60 years, people with diabetes, and periods of Delta variant predominance. CONCLUSION: All the vaccines implemented in Mexico were effective against SARS-CoV-2 infection, COVID-19 hospitalization, and death. Mass vaccination with multiple vaccines is useful to maximize vaccination coverage.

Epidemiological and clinical characteristics of patients with human monkeypox infection in Mexico: a nationwide observational study.

Background: Human monkeypox, a zoonosis historically endemic to West and South Africa, has led to a worldwide outbreak driven by human-to-human transmission resulting in an international public health emergency. Endemic and outbreak monkeypox cases may differ in their affected populations, clinical features, and outcomes. Thus, profiling cases of the current monkeypox outbreak worldwide is crucial. Methods: We performed a nationwide observational surveillance-based study from May 24 to September 5, 2022. Patients that met the operational clinical definition of monkeypox or symptomatic close contacts of confirmed cases were tested by real-time polymerase chain reaction. Clinical data were collected with a standardized case-report form. We report epidemiologic, sociodemographic, and clinical characteristics of confirmed cases. Findings: Five-hundred and sixty-five human monkeypox confirmed cases were analysed; 97.2% were men, of whom 59.5% identified as men who have sex with men, and 54.5% had human immunodeficiency virus infection. The median age was 34 years. All patients but one had rash (99.8%), 78.9% had fever, and 47.8% reported myalgia. The anogenital area was the most commonly affected one by rash (49.6%), and proctitis occurred in 6.2% of patients. Six patients required hospitalization, of which one died due to causes unrelated to monkeypox. Interpretation: The 2022 monkeypox outbreak in Mexico is mainly driven by middle-aged men who have sex with men, of which a large proportion are persons who live with human immunodeficiency virus infection. Clinical features such as the high proportion of anogenital lesions suggest sexual contact is a pivotal transmission mechanism in this outbreak. Funding: This research was supported by grant A1-S-18342 from Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico (to S.I.V.-F.).

Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community.

Objective: To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries - Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods: We compared the evolution of three tourism variables - tourist arrivals, tourist expenditure, and average length of stay - in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results: Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions: Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Caribbean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries.

This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021-2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021-2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021-2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021-2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing population-level strategies first, where most countries would reach break-even before 2030.

Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resultados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do tabagismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avaliados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community

[ABSTRACT]. Objective. To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries – Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods. We compared the evolution of three tourism variables – tourist arrivals, tourist expenditure, and aver- age length of stay – in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environ- ments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results. Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions. Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Carib- bean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

[RESUMEN]. Objetivo. Evaluar si la introducción de una legislación integral sobre ambientes libres de humo tuvo algún efecto sobre el turismo en cuatro países de la Comunidad del Caribe (CARICOM): Barbados, Guyana, Jamaica y Trinidad y Tobago. Métodos. Comparamos la evolución de tres variables turísticas (llegada de turistas, gasto de los turistas y duración promedio de la estancia) en un país que ha establecido entornos libres de humo de tabaco (país tratado) con la evolución de estas variables en el mismo país si no se hubiera adoptado una legislación sobre ambientes libres de humo. Se empleó un método de control sintético para recrear este escenario contrafáctico mediante la construcción de un país sintético utilizando un promedio ponderado de varios países del grupo de donantes de CARICOM que no habían introducido una legislación relativa a entornos libres de humo durante el período analizado. Se cuantificó el efecto de los entornos libres de humo de tabaco sobre el tur- ismo como la diferencia entre las variables turísticas en el país tratado y el sintético. Para evaluar si el efecto estimado de los entornos libres de humo fue estadísticamente significativo, se compararon los efectos de la legislación en el país tratado con los efectos placebo en el grupo de donantes mediante la suposición de que se hubiese introducido una legislación integral sobre ambientes libre de humo en el mismo año que en el país tratado. Resultados. La implementación de entornos sin humo de tabaco no tuvo ningún efecto en la llegada de tur- istas, el gasto de los turistas o la duración promedio de la estancia en los cuatro países. Conclusiones. Nuestros hallazgos ofrecen una prueba sólida de que las políticas públicas que prohíben fumar en lugares públicos no afectan a las empresas de hospitalidad y turismo. Dada la importancia económica de esta industria en el Caribe, la evidencia local proporcionada por este estudio ayudará a contrarrestar eficaz- mente la interferencia de la industria tabacalera y avanzar hacia una Comunidad del Caribe libre de humo de tabaco.

[RESUMO]. Objetivo. Avaliar se a promulgação de uma lei antifumo abrangente afetou o turismo em quatro países da Comunidade do Caribe (CARICOM), a saber: Barbados, Guiana, Jamaica e Trinidad e Tobago. Métodos. Comparamos a evolução de três variáveis relacionadas ao turismo (desembarque de turistas, des- pesas de turistas e duração média da estadia) em um país que havia implementado ambientes livres de fumo (país tratado) com a evolução dessas variáveis no mesmo país se a lei antifumo não tivesse sido implemen- tada. Usamos um método de controle sintético para recriar esse contrafactual, construindo um país sintético usando uma média ponderada de vários países doadores da CARICOM que não promulgaram leis sobre ambientes livres de fumaça durante o período analisado. Quantificamos o efeito dos ambientes livres de fumo no turismo como a diferença entre as variáveis de turismo no país tratado e no país sintético. Para avaliar se o efeito estimado dos ambientes livres de fumo foi resultado do acaso, comparamos os efeitos da legislação do país tratado com os efeitos placebo no grupo de doadores, supondo que uma lei antifumo abrangente havia sido promulgada no mesmo ano que no país tratado. Resultados. A implementação de ambientes livres de fumo não afetou o desembarque de turistas, as despe- sas de turistas ou a duração média da estadia nos quatro países. Conclusões. Nossas constatações fornecem evidências robustas de que as políticas públicas que proíbem o fumo em locais públicos não afetam o setor de hospitalidade e turismo. Considerando a importância econômica desta indústria para o Caribe, as evidências locais fornecidas por este estudo ajudarão a com- bater efetivamente a interferência da indústria do tabaco e a avançar rumo a um Caribe livre do fumo.

Case for investment in tobacco cessation: a population based analysis in low- and middle-income countries

[ABSTRACT]. This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021–2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021–2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021– 2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021–2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing popula- tion-level strategies first, where most countries would reach break-even before 2030.

[RESUMEN]. Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resul- tados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

[RESUMO]. Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do taba- gismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avali- ados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2.

BACKGROUND: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce. OBJECTIVE: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2. METHODS: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac. The factors associated with their development are determined by multivariate regression analysis. RESULTS: There were 19,163 AEFI reports during the study period; amongst them, 191 (1%) patients had psychological/psychiatric symptoms (median age of 41 years, interquartile range of 32-54; 149 [78%] women) for an observed incidence of 2.44 cases per 100,000 administered doses (95% confidence interval [CI] 2.12-2.82), 72.8% of psychiatric AEFIs were reported among recipients of BNT162b2. The median time from vaccination to symptom onset was 35 min (interquartile range: 10-720). Overall, the most common psychological/psychiatric symptoms were anxiety in 129 (67.5%) patients, panic attacks in 30 (15.7%), insomnia in 25 (13%), and agitation in 11 (5.7%). After adjusting for the confounding factors, the odds for developing psychological/psychiatric symptoms were higher for those concurrently reporting syncope (odds ratio [OR]: 4.73, 95% CI: 1.68-13.33); palpitations (OR: 2.47, 95% CI: 1.65-3.70), and dizziness (OR: 1.59, 95% CI: 1.10-2.28). CONCLUSION: In our population, psychological/psychiatric symptoms were extremely infrequent AEFIs. No severe psychiatric AEFIs were reported. Immunization stress-related responses might explain most of the detected cases.

Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.

BACKGROUND AND PURPOSE: Information on Guillain-Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS-CoV-2 remains scarce. We aimed to report GBS incidence as an AEFI among adult (≥18 years) recipients of 81,842,426 doses of seven anti-SARS-CoV-2 vaccines between December 24, 2020, and October 29, 2021, in Mexico. METHODS: Cases were retrospectively collected through passive epidemiological surveillance. The overall observed incidence was calculated according to the total number of administered doses. Vaccines were analyzed individually and by vector as mRNA-based (mRNA-1273 and BNT162b2), adenovirus-vectored (ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, and Ad26.COV2-S), and inactivated whole-virion-vectored (CoronaVac) vaccines. RESULTS: We identified 97 patients (52 males [53.6%]; median [interquartile range] age 44 [33-60] years), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97-1.45), with incidence higher among Ad26.COV2-S (3.86/1,000,000 doses, 95% CI 1.50-9.93) and BNT162b2 recipients (1.92/1,00,000 doses, 95% CI 1.36-2.71). The interval (interquartile range) from vaccination to GBS symptom onset was 10 (3-17) days. Preceding diarrhea was reported in 21 patients (21.6%) and mild COVID-19 in four more (4.1%). Only 18 patients were tested for Campylobacter jejuni (positive in 16 [88.9%]). Electrophysiological examinations were performed in 76 patients (78.4%; axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar across the platforms. On admission, 91.8% had a GBS disability score ≥3. Seventy-five patients (77.3%) received intravenous immunoglobulin, received seven plasma exchange (7.2%), and 15 (15.5%) were treated conservatively. Ten patients (10.3%) died, and 79.1% of survivors were unable to walk independently. CONCLUSIONS: Guillain-Barré syndrome was an extremely infrequent AEFI against SARS-CoV-2. The protection provided by these vaccines outweighs the risk of developing GBS.

Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.

BACKGROUND AND OBJECTIVES: Information on stroke among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines remains scarce. We report stroke incidence as an adverse event following immunization (AEFI) among recipients of 79,399,446 doses of 6 different SARS-CoV-2 vaccines (BNT162b2, ChAdOx1 nCov-19, Gam-COVID-Vac, CoronaVac, Ad5-nCoV, and Ad26.COV2-S) between December 24, 2020, and August 31, 2021, in Mexico. METHODS: This retrospective descriptive study analyzed stroke incidence per million doses among hospitalized adult patients (≥18 years) during an 8-month interval. According to the World Health Organization, AEFIs were defined as clinical events occurring within 30 days after immunization and categorized as either nonserious or serious, depending on severity, treatment, and hospital admission requirements. Acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and cerebral venous thrombosis (CVT) cases were collected through a passive epidemiologic surveillance system in which local health providers report potential AEFI to the Mexican General Board of Epidemiology. Data were captured with standardized case report formats by an ad hoc committee appointed by the Mexican Ministry of Health to evaluate potential neurologic AEFI against SARS-COV-2. RESULTS: We included 56 patients (31 female patients [55.5%]) for an overall incidence of 0.71 cases per 1,000,000 administered doses (95% CI 0.54-0.92). Median age was 65 years (interquartile range [IQR] 55-76 years); median time from vaccination to stroke (of any subtype) was 2 days (IQR 1-5 days). In 27 (48.2%) patients, the event was diagnosed within the first 24 hours after immunization. The most frequent subtype was AIS in 43 patients (75%; 0.54 per 1,000,000 doses, 95% CI 0.40-0.73), followed by ICH in 9 (16.1%; 0.11 per 1,000,000 doses, 95% CI 0.06-0.22) and SAH and CVT, each with 2 cases (3.6%; 0.03 per 1,000,000 doses, 95% CI 0.01-0.09). Overall, the most common risk factors were hypertension in 33 (58.9%) patients and diabetes in 22 (39.3%). Median hospital length of stay was 6 days (IQR 4-13 days). At discharge, functional outcome was good (modified Rankin Scale score 0-2) in 41.1% of patients; in-hospital mortality rate was 21.4%. DISCUSSION: Stroke is an exceedingly rare AEFI against SARS-CoV-2. Preexisting stroke risk factors were identified in most patients. Further research is needed to evaluate causal associations between SARS-COV-2 vaccines and stroke.

Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community / Efecto de una legislación integral sobre ambientes libres de humo en la industria del turismo en los países de la Comunidad del Caribe / Efeito de uma lei antifumo abrangente sobre a indústria do turismo em países da Comunidade do Caribe

ABSTRACT Objective. To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries - Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods. We compared the evolution of three tourism variables - tourist arrivals, tourist expenditure, and average length of stay - in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results. Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions. Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Caribbean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

RESUMEN Objetivo. Evaluar si la introducción de una legislación integral sobre ambientes libres de humo tuvo algún efecto sobre el turismo en cuatro países de la Comunidad del Caribe (CARICOM): Barbados, Guyana, Jamaica y Trinidad y Tobago. Métodos. Comparamos la evolución de tres variables turísticas (llegada de turistas, gasto de los turistas y duración promedio de la estancia) en un país que ha establecido entornos libres de humo de tabaco (país tratado) con la evolución de estas variables en el mismo país si no se hubiera adoptado una legislación sobre ambientes libres de humo. Se empleó un método de control sintético para recrear este escenario contrafáctico mediante la construcción de un país sintético utilizando un promedio ponderado de varios países del grupo de donantes de CARICOM que no habían introducido una legislación relativa a entornos libres de humo durante el período analizado. Se cuantificó el efecto de los entornos libres de humo de tabaco sobre el turismo como la diferencia entre las variables turísticas en el país tratado y el sintético. Para evaluar si el efecto estimado de los entornos libres de humo fue estadísticamente significativo, se compararon los efectos de la legislación en el país tratado con los efectos placebo en el grupo de donantes mediante la suposición de que se hubiese introducido una legislación integral sobre ambientes libre de humo en el mismo año que en el país tratado. Resultados. La implementación de entornos sin humo de tabaco no tuvo ningún efecto en la llegada de turistas, el gasto de los turistas o la duración promedio de la estancia en los cuatro países. Conclusiones. Nuestros hallazgos ofrecen una prueba sólida de que las políticas públicas que prohíben fumar en lugares públicos no afectan a las empresas de hospitalidad y turismo. Dada la importancia económica de esta industria en el Caribe, la evidencia local proporcionada por este estudio ayudará a contrarrestar eficazmente la interferencia de la industria tabacalera y avanzar hacia una Comunidad del Caribe libre de humo de tabaco.

RESUMO Objetivo. Avaliar se a promulgação de uma lei antifumo abrangente afetou o turismo em quatro países da Comunidade do Caribe (CARICOM), a saber: Barbados, Guiana, Jamaica e Trinidad e Tobago. Métodos. Comparamos a evolução de três variáveis relacionadas ao turismo (desembarque de turistas, despesas de turistas e duração média da estadia) em um país que havia implementado ambientes livres de fumo (país tratado) com a evolução dessas variáveis no mesmo país se a lei antifumo não tivesse sido implementada. Usamos um método de controle sintético para recriar esse contrafactual, construindo um país sintético usando uma média ponderada de vários países doadores da CARICOM que não promulgaram leis sobre ambientes livres de fumaça durante o período analisado. Quantificamos o efeito dos ambientes livres de fumo no turismo como a diferença entre as variáveis de turismo no país tratado e no país sintético. Para avaliar se o efeito estimado dos ambientes livres de fumo foi resultado do acaso, comparamos os efeitos da legislação do país tratado com os efeitos placebo no grupo de doadores, supondo que uma lei antifumo abrangente havia sido promulgada no mesmo ano que no país tratado. Resultados. A implementação de ambientes livres de fumo não afetou o desembarque de turistas, as despesas de turistas ou a duração média da estadia nos quatro países. Conclusões. Nossas constatações fornecem evidências robustas de que as políticas públicas que proíbem o fumo em locais públicos não afetam o setor de hospitalidade e turismo. Considerando a importância econômica desta indústria para o Caribe, as evidências locais fornecidas por este estudo ajudarão a combater efetivamente a interferência da indústria do tabaco e a avançar rumo a um Caribe livre do fumo.

Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries / Argumentos a favor de la inversión en iniciativas para el abandono del tabaco: un análisis basado en la población en países de ingreso bajo y mediano / Análise de viabilidade de investimento na cessação do tabagismo: um estudo populacional em países de baixa e média renda

ABSTRACT This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021-2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021-2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021-2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021-2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing population-level strategies first, where most countries would reach break-even before 2030.

RESUMEN Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resultados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

RESUMO Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do tabagismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avaliados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.

mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI). We found an overall frequency of 3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the arms (61%) and face/neck region (36.2%) were the most commonly affected sites. The control group had significantly higher rates of reactogenicity-associated symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54; 95% CI 0.40-0.72;p < 0.001). This is the first study describing the topography and associated factors for developing NSSS among BNT162b2 recipients. The benign nature of these symptoms may help dissipate hesitation towards this vaccine.

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.

Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.

mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.

The relationship between hospital adoption and use of high technology medical imaging and in-patient mortality and length of stay.

PURPOSE: The purpose of this paper is to investigate the relationship between hospital adoption and use of computed tomography (CT) scanners, and magnetic resonance imaging (MRI) machines and in-patient mortality and length of stay. DESIGN/METHODOLOGY/APPROACH: This study used panel data (2007-2010) from 124 hospital corporations operating in Ontario, Canada. Imaging use focused on medical patients accounting for 25 percent of hospital discharges. Main outcomes were in-hospital mortality rates and average length of stay. A model for each outcome-technology combination was built, and controlled for hospital structural characteristics, market factors and patient characteristics. FINDINGS: In 2010, 36 and 59 percent of hospitals had adopted MRI machines and CT scanners, respectively. Approximately 23.5 percent of patients received CT scans and 3.5 percent received MRI scans during the study period. Adoption of these technologies was associated with reductions of up to 1.1 percent in mortality rates and up to 4.5 percent in length of stay. The imaging use-mortality relationship was non-linear and varied by technology penetration within hospitals. For CT, imaging use reduced mortality until use reached 19 percent in hospitals with one scanner and 28 percent in hospitals with 2+ scanners. For MRI, imaging use was largely associated with decreased mortality. The use of CT scanners also increased length of stay linearly regardless of technology penetration (4.6 percent for every 10 percent increase in use). Adoption and use of MRI was not associated with length of stay. RESEARCH LIMITATIONS/IMPLICATIONS: These results suggest that there may be some unnecessary use of imaging, particularly in small hospitals where imaging is contracted out. In larger hospitals, the results highlight the need to further investigate the use of imaging beyond certain thresholds. Independent of the rate of imaging use, the results also indicate that the presence of CT and MRI devices within a hospital benefits quality and efficiency. ORIGINALITY/VALUE: To the authors' knowledge, this study is the first to investigate the combined effect of adoption and use of medical imaging on outcomes specific to CT scanners and MRI machines in the context of hospital in-patient care.

Adoption of high technology medical imaging and hospital quality and efficiency: Towards a conceptual framework.

Measuring the value of medical imaging is challenging, in part, due to the lack of conceptual frameworks underlying potential mechanisms where value may be assessed. To address this gap, this article proposes a framework that builds on the large body of literature on quality of hospital care and the classic structure-process-outcome paradigm. The framework was also informed by the literature on adoption of technological innovations and introduces 2 distinct though related aspects of imaging technology not previously addressed specifically in the literature on quality of hospital care: adoption (a structural hospital characteristic) and use (an attribute of the process of care). The framework hypothesizes a 2-part causality where adoption is proposed to be a central, linking factor between hospital structural characteristics, market factors, and hospital outcomes (ie, quality and efficiency). The first part indicates that hospital structural characteristics and market factors influence or facilitate the adoption of high technology medical imaging within an institution. The presence of this technology, in turn, is hypothesized to improve the ability of the hospital to deliver high quality and efficient care. The second part describes this ability throughout 3 main mechanisms pointing to the importance of imaging use on patients, to the presence of staff and qualified care providers, and to some elements of organizational capacity capturing an enhanced clinical environment. The framework has the potential to assist empirical investigations of the value of adoption and use of medical imaging, and to advance understanding of the mechanisms that produce quality and efficiency in hospitals.

[The masters of thoracic trauma in the Central Hospital of the Mexican Red Cross. Their story and legacy]. / Los maestros del trauma torácico en el Hospital Central de la Cruz Roja Mexicana. Su historia y legado.

The branches of medicine responsible for the care of victims of different types of injuries were born as a result of the urgent need to save lives during the wars. In Mexico, one of the first hospitals developed for the care of injured patients was the Central Hospital of the Mexican Red Cross. The aim of this article is to pay tribute to the first service for the care of patients with chest trauma, founded in 1954, its founders and those who have continued with their work: Dr. Pedro Garza Alegría, Dr. Octavio Rivas Solís Dr. Jesús Genis Becerra, etc. In 64 years of existence, there have been trained eight specialists in cardiothoracic surgery and three of them have worked in the Central Hospital of the Mexican Red Cross.

Diabetes risk reduction in primary care: Evaluation of the Ontario Primary Care Diabetes Prevention Program.

OBJECTIVES: Lifestyle interventions can reduce type 2 diabetes risk. The Primary Care Diabetes Prevention Program (PCDPP) was implemented by the Government of Ontario to lower diabetes risk. This study first evaluated the program, and second used a validated tool to estimate a potential population impact if the program were implemented more broadly in the province. METHODS: PCDPP was implemented in six primary care settings serving communities with high mortality risk due to chronic diseases. In total, 1916 adults with prediabetes or metabolic syndrome were enrolled from January 2011 to December 2012. Body weight was the primary outcome variable, and was modeled using four time periods (i.e., baseline, 3rd, 6th and 9th month). The intervention effect was estimated using multilevel mixed-effects linear regression, and was stratified by gender and age. In the population impact analysis, a number needed to treat (NNT) for the intervention to prevent one case of diabetes and an absolute number of diabetes cases averted were estimated. RESULTS: Weight loss over 9 months was 7.5% (or 6.8 kg), with 7.4% (or 6.4 kg) in females and 8.6% (or 8.6 kg) in males. When modeled, changes in weight were all statistically significant. The models for male participants predicted, however, some gains in weight in the last 3 months of the program. Dropout rates were 26.8%, 46.8% and 63.0% at 3rd, 6th and 9th month respectively. Scaling up the program would produce an NNT of approximately 36 and would avert 6401 cases of diabetes in five years. CONCLUSION: PCDPP may represent a potentially effective tool for population-level diabetes risk reduction.

FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT.

OBJECTIVES: There is widespread commitment--at least in principle--to "evidence-informed" clinical practice and policy development in health care. The intention is that only "appropriate" care ought to be delivered at public expense. Although the rationale for an appropriateness agenda is widely endorsed, and methods have been proposed for addressing it, few published studies exist of contemporary policy initiatives which have actually led to successful disinvestment. Our objective was to explore whether the direct involvement of policy stakeholders could advance appropriateness and disinvestment. METHODS: Several collaborative engagements with policy stakeholders were undertaken to adapt and combine conceptual and empirical material related to appropriateness and disinvestment from the literature to create tools and processes for use in Canada and the province of Ontario in particular. RESULTS: By combining inputs from the literature with colloquial evidence from policy stakeholders, a definition of appropriateness was developed and, importantly, endorsed by all the provincial and territorial ministers of health in Canada. Second, a reassessment framework was successfully implemented for identifying priorities for selective disinvestment. CONCLUSIONS: When scientific evidence was combined with colloquial evidence from policy stakeholders, progress was made on the design and successful implementation of policies for appropriateness and disinvestment.